From June 16 to 19, our teams attended BIO International Convention, one of the most important partnership events in the pharmaceutical sector. It was the opportunity to identify partnership opportunities that align with our strategic interests.
BIO International Convention, the place to be for partnerships
Nearly 5,000 companies — from pharmaceuticals and biotechs, to venture capital companies — participated in BIO International Convention 2025 held in Boston. In other words, a host of potential partners for our Group! Our focus was to identify opportunities that align with our strategic needs and strengthen our relationships with the companies whose development we have been following. We were also committed to answering every meeting request we received at BIO.
Every year, Servier shares its business development strategy as part of the company presentation program.
Partnership: The key to our ambition for 2030 and beyond
At Servier, we have the resources and reach of a global pharmaceutical company, combined with a long-term vision focused on developing transformative medicines for patients. Our unique value proposition enables us to build successful partnerships.
As part of our 2030 ambition, we are focusing on strategic partnerships and programmatic deal-making, mainly in oncology and neurology. We aim to drive innovation by working closely with our partners to make a meaningful impact on patient lives.
“In a highly competitive environment, we need to be recognized as a partner of choice delivering true added value in terms of innovative therapy development.”
Frédéric Scaërou, Head of Global Business Development, Servier
Our partnership strategy is driven by a single objective: accelerate the development of transformative treatments that significantly improve patient lives. We believe in a people-oriented approach to our partnerships, focusing on mutual value creation by combining our collective expertise.
Recent successes that are paving the way
In March 2025, Servier entered into a global strategic licensing agreement with Black Diamond Therapeutics for BDTX-4933, a promising Phase 1 targeted therapy in solid tumors. Through this collaboration, we have an excellent opportunity to accelerate the development of this potentially best-in-class treatment for cancer patients with RAS and RAF alterations.
A few weeks after the announcement, we continued boosting our R&D pipeline through the acquisition of BN104, a new asset from Biotech BioNova Pharmaceuticals. Currently in Phase 1/2 of clinical development, this targeted therapy offers promising results in the treatment of acute leukemia. It will strengthen our leadership in hematological cancers and our commitment to the development of precision medicine in line with our 2030 strategy.
What types of partnerships are we looking for?
Learn about our partnership interests and find contact information for the dedicated teams in our brochure.
